TLDR
- Teva Pharmaceutical stock reached a new 52-week high at $23.07, marking a 17.38% increase over the past year
- The company reported Q3 earnings of $0.78 per share, beating analyst expectations of $0.68 per share by 14.71%
- Third quarter revenue came in at $4.48 billion, exceeding the forecasted $4.36 billion
- Teva raised its Austedo guidance to $2.05-$2.15 billion for the year while adjusting full-year revenue outlook to $16.8-$17 billion
- Stock jumped 12% in premarket trading after the earnings beat and broke out of a cup-with-handle base at $19.98
Teva Pharmaceutical Industries Ltd stock reached a new 52-week high of $23.07 on Tuesday. The pharmaceutical company has seen its shares climb 17.38% over the past 12 months.
The stock’s rally accelerated Wednesday morning after Teva reported third quarter results that topped Wall Street estimates. Shares jumped 12% in premarket trading to $22.91.
The company posted adjusted earnings of $0.78 per share for the third quarter. Analysts had expected earnings of $0.68 per share. This represents an earnings surprise of 14.71%.
Revenue for the quarter reached $4.48 billion. This beat analyst forecasts of $4.36 billion. Last year during the same period, Teva earned $0.69 per share on $4.33 billion in sales.
Teva’s market capitalization now stands at $26.55 billion. The stock has delivered a 24.83% return over the past six months.
Analysts have set a price target of $29 for Teva shares. The stock currently trades near what analysts consider its fair value.
Austedo Performance Drives Guidance Update
The company raised its full-year guidance for Austedo, its movement disorders drug. Teva now expects Austedo to generate between $2.05 billion and $2.15 billion in sales for 2025.
However, Teva adjusted its overall revenue outlook for the year. The company lowered the bottom end of its sales forecast by $200 million. Full-year revenue is now projected between $16.8 billion and $17 billion.
The company also updated its earnings guidance. Teva expects adjusted earnings of $2.55 to $2.65 per share for 2025. Analysts had predicted earnings of $2.61 per share and revenue of $16.99 billion.
Technical Breakout Follows Earnings
From a technical perspective, Teva stock broke out of a cup-with-handle pattern on September 30. The stock cleared a buy point at $19.98 during that session.
After the breakout, shares briefly declined 5.8% below the entry point. This move wasn’t deep enough to trigger a typical sell rule. Tuesday saw shares return to their buy zone, which extends to $20.98.
The stock’s six-month performance has outpaced its annual gains. This suggests accelerating momentum in recent months.
According to InvestingPro data, analysts predict Teva will be profitable this year. The company was not profitable over the last twelve months. InvestingPro tracks more than 30 financial metrics for Teva.
The pharmaceutical company offers comprehensive research reports covering over 1,400 US equities through InvestingPro. These reports include exclusive financial tips and detailed analysis.
Teva’s third quarter results highlight stronger than expected performance across key metrics. The earnings beat and revenue growth demonstrate the company’s operational execution.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
